Business Description
Kezar Life Sciences Inc
NAICS : 325412
SIC : 2834
ISIN : US49372L1008
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 9.32 | |||||
Equity-to-Asset | 0.84 | |||||
Debt-to-Equity | 0.12 | |||||
Debt-to-EBITDA | -0.18 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -2.62 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -14.4 | |||||
3-Year EPS without NRI Growth Rate | -11.4 | |||||
3-Year FCF Growth Rate | -10.9 | |||||
3-Year Book Growth Rate | -5.4 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 52.44 | |||||
9-Day RSI | 58.51 | |||||
14-Day RSI | 59.26 | |||||
6-1 Month Momentum % | -32.9 | |||||
12-1 Month Momentum % | -43.78 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 9.58 | |||||
Quick Ratio | 9.58 | |||||
Cash Ratio | 9.38 | |||||
Days Sales Outstanding | 365 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -16.2 | |||||
Shareholder Yield % | 1.29 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -1422.01 | |||||
Net Margin % | -1408.11 | |||||
FCF Margin % | -1117.85 | |||||
ROE % | -51.57 | |||||
ROA % | -44.28 | |||||
ROIC % | -450.89 | |||||
3-Year ROIIC % | -542.14 | |||||
ROC (Joel Greenblatt) % | -1004.35 | |||||
ROCE % | -47.02 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 8.26 | |||||
PB Ratio | 0.38 | |||||
Price-to-Tangible-Book | 0.38 | |||||
EV-to-EBIT | 0.91 | |||||
EV-to-EBITDA | 0.93 | |||||
EV-to-Revenue | -12.67 | |||||
EV-to-FCF | 1.12 | |||||
Price-to-Net-Current-Asset-Value | 0.42 | |||||
Price-to-Net-Cash | 0.43 | |||||
Earnings Yield (Greenblatt) % | 109.89 | |||||
FCF Yield % | -136.91 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Kezar Life Sciences Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 6.559 | ||
EPS (TTM) (€) | -1.258 | ||
Beta | 0.66 | ||
Volatility % | 56.15 | ||
14-Day RSI | 59.26 | ||
14-Day ATR (€) | 0.050033 | ||
20-Day SMA (€) | 0.55325 | ||
12-1 Month Momentum % | -43.78 | ||
52-Week Range (€) | 0.462 - 1.01 | ||
Shares Outstanding (Mil) | 72.96 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Kezar Life Sciences Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Kezar Life Sciences Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Kezar Life Sciences Inc Frequently Asked Questions
What is Kezar Life Sciences Inc(STU:2KZ)'s stock price today?
When is next earnings date of Kezar Life Sciences Inc(STU:2KZ)?
Does Kezar Life Sciences Inc(STU:2KZ) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |